NASDAQ · Drug Manufacturers - Specialty & Generic · USD
Regencell Bioscience Holdings Limited (RGC) Stock Analysis
Regencell Bioscience Holdings Limited (RGC) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
RGC Key Statistics
As of Oct 21, 2026Trading
- Open
- $10.43
- Previous Close
- $10.45
- Day's Range
- 10.42–11.02
- 52-Week Range
- 4.51–69.00
- Volume
- 244.29K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.17
Valuation
- Market Cap
- $5.36B
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.02
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$4.30M
- Shares Outstanding
- 495.88M
- 1-Year Return
- −32.63%
Dividend and dates
- Earnings Date
- October 28, 2026estimated
- Avg Volume
- 238.51K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, RGC closed at $10.80, −32.63% over 1 year.
Regencell Bioscience Holdings Limited (RGC) has a market capitalization of $5.36B.
In fiscal 2024, RGC reported revenue of $0.00.
RGC Stock Return by Calendar Year
Regencell Bioscience Holdings Limited (RGC) return since Jul 2021: what $10,000 became
- 1 year
- $10,000 $6,737
- −32.63%
- 5 years
- $10,000 $241,395
- +2,313.95%
- Since Jul 2021
- $10,000 $390,879
- +3,808.79%
If you had invested $10,000 in Regencell Bioscience Holdings Limited (RGC) at the close on July 16, 2021, the earliest close on record here, it would have been worth $390,879 at the close on October 21, 2026: +3,808.79% in total, +100.63% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −48.57% |
| 2025 | +16,053.85% |
| 2024 | −52.95% |
| 2023 | −62.35% |
| 2022 | −12.44% |
| 2021 (partial year) | +203.37% |
As of October 21, 2026.
RGC Revenue and Earnings by Fiscal Year
FY ends June| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2024 | $0.00 | −$4.30M | — |
| 2023 | $0.00 | −$5.87M | — |
| 2022 | $0.00 | −$7.45M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2024 | $0.00 | — | −$4.74M | −$4.30M | — |
| 2023 | $0.00 | — | −$6.27M | −$5.87M | — |
| 2022 | $0.00 | — | −$7.62M | −$7.45M | — |
Annual figures as reported, in the company's reporting currency. As of June 30, 2024.
Recent News
How Investors Are Reacting To Regencell Bioscience Holdings (RGC) Wider Full Year Loss
YahooIs Regencell Bioscience Holdings (RGC) Fully Priced After Its Annual Loss Deepened?
YahooRegencell Bioscience: I Got It Wrong (Rating Downgrade)
SeekingAlpha
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - Specialty & Generic Stocks
Takeda Pharmaceutical Company Limited
$63.67B
TEVATeva Pharmaceutical Industries Limited
$47.37B
HLNHaleon plc
$44.06B
ZTSZoetis Inc.
$32.90B
UTHRUnited Therapeutics Corporation
$24.17B
VTRSViatris Inc.
$21.19B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B